Carla Gambarana
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Carla Gambarana has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Simona Scheggi
Department of Molecular and Developmental Medicine, University of Siena, Siena, Italy
11 shared publications - Maria Graziella De Montis
Department of Molecular and Developmental Medicine, University of Siena, Italy
5 shared publications Maria Graziella De Montis
Department of Molecular and Developmental Medicine, University of Siena
3 shared publications- Sara Salviati
Department of Molecular and Developmental Medicine, University of Siena, Siena, Italy
3 shared publications - Alberto Ferrari
FROM Research Foundation, Papa Giovanni XXIII Hospital, Bergamo, Italy
2 shared publications - Eleonora Corridori
Department of Molecular and Developmental Medicine, University of Siena, Siena, Italy
2 shared publications
Latest Publications
- Open Access
- 5 May 2026
- Published by Elsevier in Neuropharmacology
- Vol. 296, 110996
PPAR-α activation in a model of autism modulates social reward and endocannabinoid signaling selectively in male rats
- 5 May 2026
- Published by Elsevier in Neuropharmacology
- Vol. 296, 110996
Open AccessPPAR-α activation in a model of autism modulates social reward and endocannabinoid signaling selectively in male rats
- Open Access
- 13 January 2025
- Published by Elsevier in Neuropharmacology
- Vol. 267, 110302
Restorative properties of chronic lurasidone treatment on emotional dysfunction in rats exposed to chronic unavoidable stress: A role for medial prefrontal cortex - nucleus accumbens network
- 13 January 2025
- Published by Elsevier in Neuropharmacology
- Vol. 267, 110302
Open AccessRestorative properties of chronic lurasidone treatment on emotional dysfunction in rats exposed to chronic unavoidable stress: A role for medial prefrontal cortex - nucleus accumbens network
- Open Access
- 4 January 2025
- Published by Wiley in Phytotherapy Research
- Vol. 39 (3) , 1277-1291
Therapeutic Potential of Saffron Extract in Mild Depression: A Study of Its Role on Anhedonia in Rats and Humans
Drugs generally used in major depressive disorder are considered inappropriate for the more common milder forms. The efficacy of saffron extracts has been demonstrated in mild to moderate depression and in preclinical models of depression. However, evidence of saffron activity on reduced hedonic responsiveness and motivational anhedonia is limited. Since dopamine transmission dysfunctions are crucially involved in anhedonia and saffron seems to positively modulate dopamine release, we studied the potential antidepressant and anti‐anhedonic effects of a standardized formulation of saffron extract in preclinical models of anhedonia‐like behaviors, and patients diagnosed with unipolar or bipolar depression. We tested saffron activity in a rat model of stress‐induced motivational anhedonia using sucrose self‐administration protocols and investigated the molecular underpinnings of this effect focusing on DARPP‐32 phosphorylation pattern in response to a reinforcer and BDNF–TrkB signaling, in the nucleus accumbens and medial prefrontal cortex. In parallel, with a pilot double‐blind placebo‐controlled study we investigated whether saffron add‐on therapy reduced symptoms of depression and anhedonia, measured by the Montgomery–Åsberg Depression Rating Scale. Repeated saffron administration restored motivation and reactivity to reward‐associated cues in anhedonic rats, likely modulating dopaminergic transmission and BDNF–TrkB signaling. In depressed patients, an 8‐week saffron add‐on therapy induced a global improvement in depressive symptoms and a significant reduction in anhedonia. The study supports a pro‐motivational effect of saffron and suggests a potentially useful saffron‐based augmentation strategy in anhedonic patients, albeit with limitations due to small sample size and short trial duration.
- 4 January 2025
- Published by Wiley in Phytotherapy Research
- Vol. 39 (3) , 1277-1291
Open AccessTherapeutic Potential of Saffron Extract in Mild Depression: A Study of Its Role on Anhedonia in Rats and Humans
Drugs generally used in major depressive disorder are considered inappropriate for the more common milder forms. The efficacy of saffron extracts has been demonstrated in mild to moderate depression and in preclinical models of depression. However, evidence of saffron activity on reduced hedonic responsiveness and motivational anhedonia is limited. Since dopamine transmission dysfunctions are crucially involved in anhedonia and saffron seems to positively modulate dopamine release, we studied the potential antidepressant and anti‐anhedonic effects of a standardized formulation of saffron extract in preclinical models of anhedonia‐like behaviors, and patients diagnosed with unipolar or bipolar depression. We tested saffron activity in a rat model of stress‐induced motivational anhedonia using sucrose self‐administration protocols and investigated the molecular underpinnings of this effect focusing on DARPP‐32 phosphorylation pattern in response to a reinforcer and BDNF–TrkB signaling, in the nucleus accumbens and medial prefrontal cortex. In parallel, with a pilot double‐blind placebo‐controlled study we investigated whether saffron add‐on therapy reduced symptoms of depression and anhedonia, measured by the Montgomery–Åsberg Depression Rating Scale. Repeated saffron administration restored motivation and reactivity to reward‐associated cues in anhedonic rats, likely modulating dopaminergic transmission and BDNF–TrkB signaling. In depressed patients, an 8‐week saffron add‐on therapy induced a global improvement in depressive symptoms and a significant reduction in anhedonia. The study supports a pro‐motivational effect of saffron and suggests a potentially useful saffron‐based augmentation strategy in anhedonic patients, albeit with limitations due to small sample size and short trial duration.
- Open Access
- 20 May 2022
- Published by MDPI AG in Biomolecules
- Vol. 12 (5) , 723
PPARα Signaling: A Candidate Target in Psychiatric Disorder Management
Peroxisome proliferator-activator receptors (PPARs) regulate lipid and glucose metabolism, control inflammatory processes, and modulate several brain functions. Three PPAR isoforms have been identified, PPARα, PPARβ/δ, and PPARγ, which are expressed in different tissues and cell types. Hereinafter, we focus on PPARα involvement in the pathophysiology of neuropsychiatric and neurodegenerative disorders, which is underscored by PPARα localization in neuronal circuits involved in emotion modulation and stress response, and its role in neurodevelopment and neuroinflammation. A multiplicity of downstream pathways modulated by PPARα activation, including glutamatergic neurotransmission, upregulation of brain-derived neurotrophic factor, and neurosteroidogenic effects, encompass mechanisms underlying behavioral regulation. Modulation of dopamine neuronal firing in the ventral tegmental area likely contributes to PPARα effects in depression, anhedonia, and autism spectrum disorder (ASD). Based on robust preclinical evidence and the initial results of clinical studies, future clinical trials should assess the efficacy of PPARα agonists in the treatment of mood and neurodevelopmental disorders, such as depression, schizophrenia, and ASD.
- 20 May 2022
- Published by MDPI AG in Biomolecules
- Vol. 12 (5) , 723
Open AccessPPARα Signaling: A Candidate Target in Psychiatric Disorder Management
Peroxisome proliferator-activator receptors (PPARs) regulate lipid and glucose metabolism, control inflammatory processes, and modulate several brain functions. Three PPAR isoforms have been identified, PPARα, PPARβ/δ, and PPARγ, which are expressed in different tissues and cell types. Hereinafter, we focus on PPARα involvement in the pathophysiology of neuropsychiatric and neurodegenerative disorders, which is underscored by PPARα localization in neuronal circuits involved in emotion modulation and stress response, and its role in neurodevelopment and neuroinflammation. A multiplicity of downstream pathways modulated by PPARα activation, including glutamatergic neurotransmission, upregulation of brain-derived neurotrophic factor, and neurosteroidogenic effects, encompass mechanisms underlying behavioral regulation. Modulation of dopamine neuronal firing in the ventral tegmental area likely contributes to PPARα effects in depression, anhedonia, and autism spectrum disorder (ASD). Based on robust preclinical evidence and the initial results of clinical studies, future clinical trials should assess the efficacy of PPARα agonists in the treatment of mood and neurodevelopmental disorders, such as depression, schizophrenia, and ASD.
- Open Access
- 20 September 2018
- Published by Oxford University Press (OUP) in International Journal of Neuropsychopharmacology
- Vol. 21 (11) , 1049-1065
Making Sense of Rodent Models of Anhedonia
A markedly reduced interest or pleasure in activities previously considered pleasurable is a main symptom in mood disorder and psychosis and is often present in other psychiatric disorders and neurodegenerative diseases. This condition can be labeled as “anhedonia,” although in its most rigorous connotation the term refers to the lost capacity to feel pleasure that is one aspect of the complex phenomenon of processing and responding to reward. The responses to rewarding stimuli are relatively easy to study in rodents, and the experimental conditions that consistently and persistently impair these responses are used to model anhedonia. To this end, long-term exposure to environmental aversive conditions is primarily used, and the resulting deficits in reward responses are often accompanied by other deficits that are mainly reminiscent of clinical depressive symptoms. The different components of impaired reward responses induced by environmental aversive events can be assessed by different tests or protocols that require different degrees of time allocation, technical resources, and equipment. Rodent models of anhedonia are valuable tools in the study of the neurobiological mechanisms underpinning impaired behavioral responses and in the screening and characterization of drugs that may reverse these behavioral deficits. In particular, the antianhedonic or promotivational effects are relevant features in the spectrum of activities of drugs used in mood disorders or psychosis. Thus, more than the model, it is the choice of tests that is crucial since it influences which facets of anhedonia will be detected and should be tuned to the purpose of the study.
- 20 September 2018
- Published by Oxford University Press (OUP) in International Journal of Neuropsychopharmacology
- Vol. 21 (11) , 1049-1065
Open AccessMaking Sense of Rodent Models of Anhedonia
A markedly reduced interest or pleasure in activities previously considered pleasurable is a main symptom in mood disorder and psychosis and is often present in other psychiatric disorders and neurodegenerative diseases. This condition can be labeled as “anhedonia,” although in its most rigorous connotation the term refers to the lost capacity to feel pleasure that is one aspect of the complex phenomenon of processing and responding to reward. The responses to rewarding stimuli are relatively easy to study in rodents, and the experimental conditions that consistently and persistently impair these responses are used to model anhedonia. To this end, long-term exposure to environmental aversive conditions is primarily used, and the resulting deficits in reward responses are often accompanied by other deficits that are mainly reminiscent of clinical depressive symptoms. The different components of impaired reward responses induced by environmental aversive events can be assessed by different tests or protocols that require different degrees of time allocation, technical resources, and equipment. Rodent models of anhedonia are valuable tools in the study of the neurobiological mechanisms underpinning impaired behavioral responses and in the screening and characterization of drugs that may reverse these behavioral deficits. In particular, the antianhedonic or promotivational effects are relevant features in the spectrum of activities of drugs used in mood disorders or psychosis. Thus, more than the model, it is the choice of tests that is crucial since it influences which facets of anhedonia will be detected and should be tuned to the purpose of the study.
- Open Access
- 25 July 2018
- Published by Wiley in Journal of Neurochemistry
- Vol. 147 (4) , 439-453
DARPP‐32 in the orchestration of responses to positive natural stimuli
Dopamine‐ and cAMP‐regulated phosphoprotein (Mr 32 kDa, DARPP‐32) is an integrator of multiple neuronal signals and plays a crucial role particularly in mediating the dopaminergic component of the systems involved in the evaluation of stimuli and the ensuing elaboration of complex behavioral responses (e.g., responses to reinforcers and stressors). Dopamine neurons can fire tonically or phasically in distinct timescales and in specific brain regions to code different behaviorally relevant information. Dopamine signaling is mediated mainly through the regulation of adenylyl cyclase activity, stimulated by D1‐like or inhibited by D2‐like receptors, respectively, that modulates cAMP‐dependent protein kinase (PKA) function. The activity of DARPP‐32 is finely regulated by its phosphorylation at multiple sites. Phosphorylation at the threonine (Thr) 34 residue by PKA converts DARPP‐32 into an inhibitor of protein phosphatase 1, while the phosphorylation at the Thr75 residue turns it into an inhibitor of PKA. Thus, DARPP‐32 is critically implicated in regulating striatal output in response to the convergent pathways that influence signaling of the cAMP/PKA pathway. This review summarizes some of the landmark and recent studies of DARPP‐32‐mediated signaling in the attempt to clarify the role played by DARPP‐32 in the response to rewarding natural stimuli. Particularly, the review deals with data derived from rodents studies and discusses the involvement of the cAMP/PKA/DARPP‐32 pathway in: 1) appetitive food‐sustained motivated behaviors, 2) motivated behaviors sustained by social reward, 3) sexual behavior, and 4) responses to environmental enrichment. image
- 25 July 2018
- Published by Wiley in Journal of Neurochemistry
- Vol. 147 (4) , 439-453
Open AccessDARPP‐32 in the orchestration of responses to positive natural stimuli
Dopamine‐ and cAMP‐regulated phosphoprotein (Mr 32 kDa, DARPP‐32) is an integrator of multiple neuronal signals and plays a crucial role particularly in mediating the dopaminergic component of the systems involved in the evaluation of stimuli and the ensuing elaboration of complex behavioral responses (e.g., responses to reinforcers and stressors). Dopamine neurons can fire tonically or phasically in distinct timescales and in specific brain regions to code different behaviorally relevant information. Dopamine signaling is mediated mainly through the regulation of adenylyl cyclase activity, stimulated by D1‐like or inhibited by D2‐like receptors, respectively, that modulates cAMP‐dependent protein kinase (PKA) function. The activity of DARPP‐32 is finely regulated by its phosphorylation at multiple sites. Phosphorylation at the threonine (Thr) 34 residue by PKA converts DARPP‐32 into an inhibitor of protein phosphatase 1, while the phosphorylation at the Thr75 residue turns it into an inhibitor of PKA. Thus, DARPP‐32 is critically implicated in regulating striatal output in response to the convergent pathways that influence signaling of the cAMP/PKA pathway. This review summarizes some of the landmark and recent studies of DARPP‐32‐mediated signaling in the attempt to clarify the role played by DARPP‐32 in the response to rewarding natural stimuli. Particularly, the review deals with data derived from rodents studies and discusses the involvement of the cAMP/PKA/DARPP‐32 pathway in: 1) appetitive food‐sustained motivated behaviors, 2) motivated behaviors sustained by social reward, 3) sexual behavior, and 4) responses to environmental enrichment. image
- 1 June 2017
- Published by Elsevier in Neuroscience
- Vol. 352, 19-29
Fasting biases μ -opioid receptors toward β –arrestin2-dependent signaling in the accumbens shell
- 1 June 2017
- Published by Elsevier in Neuroscience
- Vol. 352, 19-29
Fasting biases μ -opioid receptors toward β –arrestin2-dependent signaling in the accumbens shell
- 1 April 2015
- Published by Elsevier in Neuroscience
- Vol. 291, 189-202
Impramine, fluoxetine and clozapine differently affected reactivity to positive and negative stimuli in a model of motivational anhedonia in rats
- 1 April 2015
- Published by Elsevier in Neuroscience
- Vol. 291, 189-202
Impramine, fluoxetine and clozapine differently affected reactivity to positive and negative stimuli in a model of motivational anhedonia in rats